BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing
BioHarvest Sciences (NASDAQ: BHST) plans to list its shares on the Tel Aviv Stock Exchange (TASE) by September 8, 2026, alongside its Nasdaq listing. The company, which develops plant-based molecules, aims to provide Israeli investors with access to its shares. BioHarvest filed to register 22.67 million outstanding shares and up to 5.13 million additional shares. CEO Zaki Rakib stated this move supports the company's growth and global ambitions.
How this was made
The 30-second read
Why it matters
The announcement provides new capital‑raising avenues and may improve liquidity, but execution risk remains until the Sep 8 start date.
Market read
First‑report of a dual‑listing plan for a small‑cap biotech, offering a modest trading opportunity around the Sep 8, 2026 start.
What to watch
Potential costs of maintaining two listings and limited trading history on TASE could temper price gains.
Background
BioHarvest Sciences Inc (NASDAQ:BHST) is a plant‑based molecule developer planning a secondary listing on the Tel Aviv Stock Exchange.
Ticker impact
BioHarvest Sciences announced a dual listing on the Tel Aviv Stock Exchange with trading to start Sep 8, 2026.
Potential modest upside as Israeli investors gain direct access; short-term volatility possible around listing date.
Dual listings are rare for small-cap biotech; the announcement is a primary disclosure and may attract new capital.
Market effects
May highlight increased interest in Israeli‑origin biotech firms and plant‑based molecule space.
Could add modest volume to the Tel Aviv market and attract foreign investors to TASE.
Limited to niche biotech investors; not a broad market driver.
Counterpoint
The dual listing may dilute existing shareholders and add regulatory complexity, limiting upside.
Key entities
- companyBioHarvest Sciences Inc
NASDAQ‑listed biotech developing plant‑based molecules.
- exchangeTel Aviv Stock Exchange
Israel's primary securities market where BHST will be listed.
